Safety Concerns Spur Aardvark to Halt Key Prader-Willi Drug Trial

Why It Matters

The halt underscores the fragile therapeutic window for ARD‑101 and could reshape investor confidence in the $10 billion Prader‑Willi market, influencing future funding and regulatory scrutiny.

Key Takeaways

• Phase 3 ARD‑101 trial paused due to reversible cardiac signals
• Shares fell over 50%, trading below $6 per share
• Prader‑Willi market estimated at $10 billion, high unmet need
• Higher doses triggered EKG changes not seen at therapeutic levels
• Regulators may scrutinize safety given PWS cardiovascular comorbidities

Pulse Analysis

Aardvark Therapeutics’ decision to suspend dosing in its Phase 3 HERO study reflects a broader tension in rare‑disease drug development: balancing rapid progress with rigorous safety oversight. The cardiac signals emerged during a high‑dose safety cohort, a standard precautionary step that revealed reversible EKG changes. While the observations occurred at doses above the therapeutic target, they raise questions about the drug’s mechanism—activation of gut‑localized bitter‑taste receptors that also exist in cardiac tissue. This safety signal forces the company to re‑evaluate the therapeutic window before resuming enrollment, a process that could push back anticipated data read‑outs and strain cash reserves.

The market impact was immediate. Aardvark’s stock plunged more than half, erasing roughly $300 million in market value, while competitors like Soleno Therapeutics saw modest gains as investors search for alternative Prader‑Willi candidates. Analysts estimate the addressable market for PWS therapies at $10 billion, driven by unmet appetite‑control needs and recent FDA approval of Soleno’s Vykat. However, safety concerns surrounding Vykat have already softened its growth outlook, suggesting that any new entrant must demonstrate a clear safety advantage. The pause may also affect Aardvark’s ability to secure follow‑on financing, prompting a reassessment of its IPO proceeds and partnership prospects.

From a scientific perspective, the episode highlights the challenges of targeting receptors with widespread tissue distribution. Bitter‑taste receptors, while promising for modulating gut hormones, are also expressed in the heart and lungs, making off‑target effects plausible. The reversible nature of the EKG changes offers some reassurance, yet regulators will likely demand robust cardiac monitoring in subsequent cohorts. Should Aardvark successfully define a narrow but safe dosing range, it could still carve a niche in a market hungry for safer, effective treatments. Until then, the company faces heightened scrutiny from the FDA and clinicians wary of adding cardiovascular risk to a patient population already burdened with high morbidity.